Rchr
J-GLOBAL ID：201801001165630550
Update date: Apr. 14, 2024
Eda Takeyoshi
Eda Takeyoshi
Affiliation and department：
Research field (1)：
Pharmacology
Research theme for competitive and other funds (2)：
- 2020 - 2023 Establishment of drug therapy targeting metabolic reprogramming for glioblastoma
- 2017 - 2020 Foundation of chemotherapy for malignant glioma targeting mTOR
Papers (18)：
-
Jotaro On, Manabu Natsumeda, Haruhiko Takahashi, Akihide Koyama, Satoshi Shibuma, Nao Shibata, Jun Watanabe, Shoji Saito, Yu Kanemaru, Yoshihiro Tsukamoto, et al. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors. Journal of neuro-oncology. 2024
-
Yoshihiro Tsukamoto, Manabu Natsumeda, Haruhiko Takahashi, Asuka Ueno, Kiichi Sakai, Kazuki Shida, Hiroki Seto, Taiki Saito, Satoshi Shibuma, Yoko Nakayama, et al. Clinical, imaging, and molecular features of radiation-induced glioblastomas developing more than 20 years after radiation therapy for intracranial germinomatous germ cell tumor: illustrative cases. Journal of neurosurgery. Case lessons. 2023. 6. 16
-
Kazuhiro Ando, Manabu Natsumeda, Masahide Kawamura, Kamon Shirakawa, Masayasu Okada, Yoshihiro Tsukamoto, Takeyoshi Eda, Jun Watanabe, Shoji Saito, Haruhiko Takahashi, et al. Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas. Thrombosis research. 2023. 223. 36-43
-
Yoshihiro Mouri, Manabu Natsumeda, Noritaka Okubo, Taro Sato, Taiki Saito, Kohei Shibuya, Shiori Yamada, Jotaro On, Yoshihiro Tsukamoto, Masayasu Okada, et al. Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate-Case Report. Journal of Clinical Medicine. 2022. 11. 19. 5548-5548
-
Takeyoshi Eda, Masayasu Okada, Ryosuke Ogura, Yoshihiro Tsukamoto, Yu Kanemaru, Jun Watanabe, Jotaro On, Hiroshi Aoki, Makoto Oishi, Nobuyuki Takei, et al. Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. Cancers. 2022. 14. 3
ｍore...
Return to Previous Page
